L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile

2018139 citationsJournal Articlehybrid Open Access

Authors

F. Kommoss · Heidelberg University

Anthony N. Karnezis · BC Cancer Agency

Friedrich Kommoss · Medizin Campus Bodensee

Aline Talhouk · University of British Columbia

Florin‐Andrei Taran · University Children's Hospital Tübingen

Annette Staebler · University Children's Hospital Tübingen

C. Blake Gilks

Abstract

L1CAM status was able to significantly stratify risk among tumours of the large p53 wt/NSMP ProMisE subgroup of EC. Furthermore, our study confirms a highly significant correlation between mutation-type p53 immunostaining and abnormal L1CAM expression in EC.

Topics & Keywords

Endometrial and Cervical Cancer Treatments Cancer Cells and Metastasis MicroRNA in disease regulation

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: British Journal of Cancer

Volume 119, Issue 4, pp. 480-486

DOI: 10.1038/s41416-018-0187-6

Field-Weighted Citation Impact: 6.67